Royalty Pharma Strikes Deal on FDA-Approved Schizophrenia Drug
Company Announcements

Royalty Pharma Strikes Deal on FDA-Approved Schizophrenia Drug

Royalty Pharma ( (RPRX) ) has shared an update.

Bristol Myers Squibb has gained FDA approval for KarXT, a new schizophrenia treatment for adults, which will be sold under the name Cobenfy. Following a royalty agreement, Royalty Pharma has made a $100 million payment to PureTech Health, with the potential for $400 million more based on future milestones. They will receive royalties from Cobenfy sales, which are set at 3% until annual sales reach $2 billion, then dropping to 1%. The FDA’s approval has triggered a $25 million milestone payment from Royalty Pharma to PureTech.

For detailed information about RPRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyRoyalty Pharma enters $350M synthetic royalty funding agreement with Syndax
TheFlySyndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
Michael MarcusMorgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App